Yoshiki Kawabe
Yokohama, 2449602, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Utilization of phase I studies for target validation of first-in-class drugs.
Journal: Drug discovery today
Published: July 09, 2024
A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state.
Journal: Journal of thrombosis and haemostasis : JTH
Published: June 14, 2023
Novel myostatin-specific antibody enhances muscle strength in muscle disease models.
Journal: Scientific reports
Published: November 26, 2020
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 12, 2020
Optimization of PTH/PTHrP Hybrid Peptides to Derive a Long-Acting PTH Analog (LA-PTH).
Journal: JBMR plus
Published: March 20, 2020
Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation.
Journal: Cancer discovery
Published: March 17, 2020
Evidence of an intestinal phosphate transporter alternative to type IIb sodium-dependent phosphate transporter in rats with chronic kidney disease.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: February 28, 2020
Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.
Journal: PloS one
Published: September 10, 2018
Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
Journal: Journal of thrombosis and haemostasis : JTH
Published: February 15, 2018
Inhibin βE (INHBE) is a possible insulin resistance-associated hepatokine identified by comprehensive gene expression analysis in human liver biopsy samples.
Journal: PloS one
Published: September 20, 2017
Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro.
Journal: TH open : companion journal to thrombosis and haemostasis
Published: August 15, 2017
Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens.
Journal: Thrombosis and haemostasis
Published: January 15, 2017
Last Updated: 09/26/2026